Aktuellt
SENASTE
The main point is to secure interest among leading centres and initiate evaluation processes at this launch stage. During Q4, Hansa can point towards product sales, and Idefirix has probably been delivered to treat three patients. Hansa's Q4 update reflects a step in the right direction as the launch advances ahead of more substantial sales in 2023 and beyond.
LÄS MER
